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ABSTRACT
Objectives: Anti-epidermal growth factor receptor (EGFR) therapy has been 
found to be more effective against left-sided colorectal cancer (LCRC) than right-
sided colorectal cancer (RCRC). We hypothesized that RCRC is more likely to harbor 
genetic alterations associated with resistance to anti-EGFR therapy and tested this 
using comprehensive genomic sequencing.
Materials and methods: A total of 201 patients with either primary RCRC or LCRC 
were analyzed. We investigated tumors for genetic alterations using a 415-gene 
panel, which included alterations associated with resistance to anti-EGFR therapy: 
TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), RAS pathway (KRAS, NRAS, 
HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA). Patients whose 
tumors had no alterations in these 12 genes, theoretically considered to respond to 
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anti-EGFR therapy, were defined as “all wild-type”, while remaining patients were 
defined as “mutant-type”.
Results: Fifty-six patients (28%) and 145 patients (72%) had RCRC and LCRC, 
respectively. Regarding genetic alterations associated with anti-EGFR therapy, only 
6 of 56 patients (11%) with RCRC were “all wild-type” compared with 41 of 145 
patients (28%) with LCRC (P = 0.009). Among the 49 patients who received anti-EGFR 
therapy, RCRC showed significantly worse progression-free survival (PFS) than LCRC 
(P = 0.022), and “mutant-type” RCRC showed significantly worse PFS compared with 
“all wild-type” LCRC (P = 0.004).
Conclusions: RCRC is more likely to harbor genetic alterations associated with 
resistance to anti-EGFR therapy compared with LCRC. Furthermore, our data shows 
primary tumor sidedness is a surrogate for the non-random distribution of genetic 
alterations in CRC.
INTRODUCTION
The colon is an embryological derivative of the midgut 
and hindgut separately, and thus the right-sided colon, the left-
sided colon, and the rectum each have different anatomical 
and physiological features. Evidence shows that tumors 
arising from right colon have distinct clinical and biological 
characteristics compared with tumors of the left colon or 
rectum [1-6]. Right-sided colorectal cancer (RCRC) is 
generally characterized by being more common in women, 
and associated with Lynch syndrome, the serrated pathway, 
Mitogen-activated protein kinase signaling, microsatellite 
instability-high (MSI-H), deficiency of mismatch repair genes, 
CpG island methylation, and KRAS and BRAF mutations [7-
10]. Left-sided colorectal cancer (LCRC) is more common 
in men, and associated with familial adenomatous polyposis 
syndrome, Wnt and EGFR signaling, chromosomal instability, 
ERBB1 and ERBB2 amplifications, and APC, p53, and NRAS 
mutations [10, 11]. Based on these molecular differences, 
sidedness of CRC is thought to be associated with efficacy of 
chemotherapy and targeted therapy.
The monoclonal antibodies cetuximab and 
panitumumab are epidermal growth factor receptor 
(EGFR) inhibitors that block downstream signaling 
of the EGFR pathway. Randomized phase III clinical 
trials have shown a survival benefit of these anti-EGFR 
monoclonal antibodies in RAS wild-type metastatic CRC 
[12-14]; however, tumor location has not traditionally 
been included as a stratification criterion in clinical 
trials. Recently, several retrospective, unplanned analyses 
examined primary tumor sidedness and revealed that anti-
EGFR therapy clearly benefitted patients with LCRC, 
whereas patients with RCRC derived limited benefit [15-
17]. Consequently, while these analyses were limited by 
low numbers of RCRC patients, the related imbalance 
between groups, and no randomization; primary tumor 
sidedness of CRC has emerged as new predictive marker 
for efficacy of anti-EGFR therapy.
The mechanism of resistance to anti-EGFR therapy 
in patients with RCRC has not been fully elucidated. 
Although RAS mutations are established biomarkers of 
efficacy to anti-EGFR therapy, anti-EGFR therapy is not 
effective for all patients with a RAS wild-type tumor [18-
21]. Genetic alterations in tyrosine kinase (TK) receptors, 
the RAS pathway (other than KRAS and NRAS mutations), 
and the PI3K pathway are other possible mechanisms of 
resistance to anti-EGFR therapy [22, 23]. While the most 
clinically important alterations, such as KRAS, NRAS, 
and BRAF mutations, have been widely analyzed among 
patients with metastatic CRC, the other alterations have 
not been widely studied.
Next-generation sequencing projects, such as The 
Cancer Genome Atlas, have profiled genomic changes 
in many cancers including CRC [24]. We have similarly 
reported a genomic analysis of Japanese CRC patients 
using comprehensive genomic sequencing (CGS) [25, 26]. 
CGS detects gene mutations and copy number alterations 
in TK receptors, and the RAS and PI3K pathway in a 
single assay. In the present analysis, we hypothesized 
that RCRC more frequently harbors genetic alterations 
associated with resistance to anti-EGFR therapy compared 
with LCRC. To test this hypothesis, we investigated these 
genetic alterations using CGS.
RESULTS
Association between primary tumor sidedness 
and clinicopathological characteristics
Fifty-six patients (28%) and 145 patients (72%) had 
RCRC and LCRC, respectively (Figure 1). Histopathological 
grade 3 was significantly associated with RCRC (P < 0.001; 
Table 1). Medullary type, mucinous type, and MLH1/MSH2 
status were significantly associated with RCRC (P = 0.022, 
P = 0.007, and P = 0.024, respectively; Table 2).
Association between primary tumor sidedness 
and genetic alterations evaluated using CGS
CGS of the 415-gene panel in our cohort of 
201 patients detected genetic alterations in 268 genes 
(Supplementary Table 1). Mutations in KRAS, PIK3CA, 
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RNF43, BRAF, ACVR2A, MSH6, and PALB2 were 
significantly associated with RCRC (P = 0.047, P = 0.014, 
P = 0.039, P < 0.001, P = 0.003, P = 0.016, and P = 0.001, 
respectively; Figure 2), and mutations in APC, TP53 and 
PTCH1 were significantly associated with LCRC (P = 
0.010, P = 0.005, and P = 0.036, respectively; Figure 2). 
The hypermutated tumor was significantly associated with 
RCRC (P = 0.008; Table 2). Genetic alterations found in 
the 12 genes associated with resistance to anti-EGFR 
therapy (TK receptors: ERBB2, MET, EGFR, FGFR1, and 
PDGFRA; RAS pathway: KRAS, NRAS, HRAS, BRAF, 
and MAPK2K1; and PI3K pathway: PTEN and PIK3CA) 
are detailed in Supplementary Table 2. Of the 201 patients, 
154 harbored one or more genetic alterations in these 12 
genes with 80, 63, 8, 2, and 1 patients had 1, 2, 3, 4, and 
5 gene alterations, respectively. Of the 56 RCRC patients, 
6 (11%) were wild-type in all 12 genes (termed “all wild-
type”); while 41 of 145 patients (28%) of LCRC were “all 
wild-type” (P = 0.009; Figure 3, Table 3).
Efficacy of anti-EGFR therapy according to 
primary tumor sidedness and genetic alterations 
associated with resistance to anti-EGFR therapy
Among the 49 patients treated with anti-EGFR 
therapy in addition to cytotoxic chemotherapy, patients 
with RCRC showed significantly worse progression-
free survival (PFS) than patients with LCRC (P = 0.022; 
Figure 4A). Regarding the 12 genes associated with anti-
EGFR therapy resistance in these 49 patients, 18, 25, and 
6 patients had 0, 1 and 2 genetic alterations, respectively. 
No significant difference was observed in PFS between 
“all wild-type” and “mutant-type” (Figure 4B), but the six 
patients with two genetic alterations showed significantly 
worse PFS than patients with no genetic mutations (P = 
0.005; Figure 4C). After stratification by primary tumor 
sidedness, we found BRAF mutations were significantly 
associated with RCRC (P = 0.047; Table 4). When the 
49 patients were classified into four groups according to 
primary tumor sidedness and genetic alterations associated 
with anti-EGFR therapy resistance, “mutant-type” RCRC 
showed a significantly worse PFS compared with “all 
wild-type” LCRC (P = 0.004; Figure 4D).
DISCUSSION
CGS analysis of genetic alterations in 201 primary 
CRCs revealed important genetic differences in relation to 
tumor sidedness: that there are genetic alterations in RCRC 
that are distinct from LCRC, and that CRCs wild-type in 
TK receptors and the RAS and PI3K pathways (termed 
“all wild-type” tumors and theoretically more likely to 
respond to anti-EGFR therapy), were significantly less 
common amongst RCRC. These genetic differences likely 
Figure 1: Primary tumor locations in right-sided colorectal cancer and left-sided colorectal cancer. RCRC, right-sided 
colorectal cancer; LCRC, left-sided colorectal cancer.
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drive the inherent resistance of RCRCs to anti-EGFR 
therapy.
Primary tumor sidedness of CRC has prognostic 
importance and relates to response to targeted therapy 
[15-18]. Recent meta-analyses reported that RCRC was 
a negative prognostic variable independent of Tumor-
Node-Metastasis (TNM) stage [16]. Furthermore, patients 
with RAS wild-type LCRC had significantly greater 
survival benefit from anti-EGFR therapy compared with 
anti-vascular endothelial growth factor (VEGF) therapy; 
and, conversely, RCRC had poor benefit from standard 
therapies including anti-EGFR therapy, but was associated 
with longer survival with anti-VEGF therapy [17, 18]. 
The National Comprehensive Cancer Network (NCCN) 
guidelines noted that cetuximab and panitumumab confer 
little, if any, benefit to patients with metastatic CRC 
if the primary tumor originated on the right side, and 
primary tumor sidedness is a surrogate for the non-random 
distribution of molecular subtypes [18]. However, the 
molecular background of RCRC and LCRC has not been 
fully elucidated, and it is still unclear why anti-EGFR 
therapy is less efficacious in patients with RCRC compared 
with patients with LCRC. Hence, we investigated genomic 
differences between RCRC and LCRC using CGS, focusing 
on identifying the mechanism driving the observed 
difference in response to anti-EGFR therapy.
Table 1: Association between primary tumor sidedness and clinicopathological characteristics (N = 201)
Primary tumor sidedness
P-valueVariable Right (n = 56) Left (n = 145)
Age (years)
 < 65 22 78 0.065
  ≥ 65 34 67
Sex
 Male 29 55 0.074
 Female 27 90
Tumor size (mm)
 < 50 23 65 0.630
  ≥ 50 33 80
T category
 T1, 2 6 18 0.739
 T3, 4 50 127
Histopathological grading
 G1, 2 31 116 < 0.001
 G3 25 29
Lymphatic invasion
 Absence 18 61 0.196
 Presence 38 84
Venous invasion
 Absence 10 38 0.213
 Presence 46 107
N category
 N0 13 46 0.235
 N1, 2 43 99
M category
 M0 22 68 0.331
 M1 34 77
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Table 2: Primary tumor sidedness and pathological and genetic characteristics related with deficiency of mismatch 
repair genes (N = 201)
Primary tumor sidedness
P-valueVariable Right (n = 56) Left (n = 145)
Medullary type
 Yes 52 144 0.022
 No 4 1
Mucinous type
 Yes 47 139 0.007
 No 9 6
Signet ring type
 Yes 55 143 0.999
 No 1 2
Tumor infiltrating lymphocytesa
 Yes 13 23 0.223
 No 43 122
MLH1/MSH2 status
 Normal 22 69 0.013
 Abnormal 10 9
Hypermutated phenotype
 Hypermutated 10 7 0.008
 Non-hypermutated 46 138
a Cut-off value = 10 lymphocytes/5 high power fields.
Figure 2: Distribution of genetic alterations in right-sided and left-sided colorectal cancer. Dark bars indicate genes with 
a significant difference (P < 0.05, two-tailed Fisher’s exact test or Chi-squared test) in the frequency of genetic alterations compared with 
other-sided donors. Light bars indicate genes that are not significantly different (*, P < 0.05; **, P < 0.01). The genes associated with anti-
EGFR resistance were highlighted.
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CGS has been shown to detect numerous genetic 
alterations, including driver mutations, in many solid cancers 
[24, 25]. Mutations in the RAS pathway, such as KRAS, 
NRAS, and BRAF, are benchmarks to determine treatment 
strategies for patients with metastatic CRC. The NCCN 
guidelines state that all patients with metastatic CRC should 
have tumor tissue genotyped for KRAS, NRAS, and BRAF 
mutations, and patients with any known KRAS or NRAS 
mutation should not be treated with anti-EGFR therapy such 
as cetuximab and panitumumab [18]. In the present analysis, 
we assumed that genetic alterations in TK receptors, the RAS 
pathway, or the PI3K pathway are possible mechanisms 
underlying resistance to anti-EGFR therapy [22, 23]. We 
successfully detected genetic alterations, not only in the RAS 
pathway, but also among TK receptors and the PI3K pathway 
that may be associated with resistance to anti-EGFR therapy. 
Furthermore, patients with RCRC showed a significantly 
worse PFS than those with LCRC.
Cancer genome profiling seeks to enable precision 
medicine, modifying therapies based on the unique genomic 
changes inherent in the individual tumor of each patient. 
In the present analysis, we showed an association between 
tumor sidedness and gene mutations, which may explain 
the difference in efficacy of anti-EGFR therapy in RCRC 
compared with LCRC. The genomic background of RCRC 
as revealed by CGS is consistent with the results of previous 
meta-analyses [15-17] and the NCCN guidelines regarding 
the relevance of tumor sidedness [18]. However, we also 
demonstrated that approximately 10% of RCRC patients 
had the “all wild-type” phenotype with no mutations 
detected in TK receptors or the RAS or PI3K pathways, and 
therefore, theoretically, these patients would be considered 
as responders to anti-EGFR therapy despite having 
RCRC. As such, while we showed that RCRC commonly 
demonstrates a genomic profile associated with resistance 
to anti-EGFR therapy, we propose future analyses should 
focus on individual tumors rather than primary tumor 
sidedness to best facilitate precision medicine.
CGS has ability to detect numerous actionable 
mutations that can guide new treatment strategies. In this 
analysis, a novel finding was PALB2 mutations occurring 
significantly more frequent in RCRC than LCRC. PALB2 is 
a DNA maintenance gene, where the encoded protein binds 
to and colocalizes with BRCA2 in nuclear foci, and plays 
a role of tumor suppression [27]. In CRC, the significance 
of PALB2 mutations has not been elucidated, and this is the 
first report regarding PALB2 mutations in relation to CRC 
sidedness. PALB2 mutations are considered to be actionable, 
Figure 3: Percentage of genetic alterations associated with resistance to anti-EGFR therapy in right-sided colorectal 
cancer and left-sided colorectal cancer. Genetic alterations in TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), RAS 
pathway (KRAS, NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA) were evaluated using comprehensive 
genomic sequencing of the 415-gene panel. Patients who had no alterations in all 12 genes were defined as “all wild-type”. RCRC, right-
sided colorectal cancer; LCRC, left-sided colorectal cancer.
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Table 3: Association between primary tumor sidedness and gene alterations of TK receptors/RAS pathway/PI3K 
pathway (N = 201)
Primary tumor sidedness
P-valueVariable Right (n = 56) Left (n = 145)
ERBB2 status
 Wild-type 54 132 0.243
 Mutanta 2 13
MET status
 Wild-type 55 139 0.676
 Mutanta 1 6
EGFR status
 Wild-type 56 141 0.578
 Mutant 0 4
FGFR1 status
 Wild-type 56 135 0.065
 Mutant 0 10
PDGFRA status
 Wild-type 55 144 0.481
 Mutant a 1 1
KRAS status
 Wild-type 29 97 0.047
 Mutant 27 48
NRAS status
 Wild-type 54 142 0.620
 Mutant 2 3
HRAS status
 Wild-type 55 143 0.999
 Mutant 1 2
BRAF status
 Wild-type 41 136 < 0.001
 Mutant 15 9
MAPK2K1 status
 Wild-type 54 137 0.729
 Mutant 2 8
PTEN status
 Wild-type 39 107 0.554
 Mutant b 17 38
PIK3CA status
 Wild-type 41 127 0.014
 Mutant 15 18
(Continued)
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and are a biomarker for response to Poly (ADP-ribose) 
polymerase (PARP) inhibitors in pancreatic (ClinicalTrials.
gov Identifier: NCT03140670) and prostatic (ClinicalTrials.
gov Identifier: NCT02952534) cancers. In this analysis, we 
found 8 of 56 (14%) RCRCs had PALB2 mutations compared 
with 3 of 145 (2%) LCRCs. Thus, targeting PALB2 may 
represent a future treatment strategy for RCRC.
To the best of our knowledge, this is the first report 
describing a genomic overview of RCRC and LCRC using 
CGS. However, this analysis has several limitations. First, 
it was a retrospective analysis performed at two institutions 
and included a relatively small number of patients. Second, 
the selection of genomic biomarkers of resistance outside of 
RAS is not yet well supported by prospective studies. Third, 
Primary tumor sidedness
P-valueVariable Right (n = 56) Left (n = 145)
Alterations in TK receptors/RAS 
pathway/PI3K pathway
 0 6 41 0.024
 1 24 56
 2 or more 26 48
 All wild-type 6 41 0.009
 Mutant-type 50 104
a Including mutation and amplification.
b Including mutation and deletion
Figure 4: Progression-free survival of patients who received anti-EGFR therapy in addition to cytotoxic chemotherapy. 
(A) Progression-free survival stratified by primary tumor sidedness. (B) Progression-free survival stratified by genetic alterations associated 
with resistance to anti-EGFR therapy. (C) Progression-free survival stratified by the number of genetic alterations associated with resistance 
to anti-EGFR therapy. (D) Progression-free survival stratified by primary tumor sidedness and genetic alterations. “All wild-type” indicates 
patients without any genetic alterations associated with resistance to anti-EGFR therapy, and “mutant-type” indicates those with one or 
more genetic alterations. RCRC, right-sided colorectal cancer; LCRC, left-sided colorectal cancer.
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Table 4: Association between primary tumor sidedness and clinicopathological characteristics in 49 patients with 
anti-EGFR therapy in addition to cytotoxic chemotherapy
Primary tumor sidedness
P-valueVariable Right (n = 8) Left (n = 41)
Age (years)
 < 65 4 27 0.443
  ≥ 65 4 14
Sex
 Male 4 27 0.443
 Female 4 14
Tumor size (mm)
 < 50 5 19 0.463
  ≥ 50 3 22
T category
 T2, 3 4 18 0.999
 T4 4 23
Histopathological grading
 G1, 2 3 32 0.033
 G3 5 9
Lymphatic invasion
 Absence 1 14 0.406
 Presence 7 27
Venous invasion
 Absence 2 6 0.601
 Presence 6 35
N category
 N0 1 5 0.999
 N1, 2 7 36
M category
 M0 1 1 0.421
 M1a 4 23
 M1b 3 17
KRAS status
 Wild-type 7 39 0.421
 Mutant 1 2
BRAF status
 Wild-type 5 38 0.047
 Mutant 3 3
(Continued)
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as patients who received anti-EGFR therapy were analyzed 
retrospectively, we could not definitively associate primary 
tumor sidedness with response to anti-EGFR therapy. Fourth, 
as the number of RCRC patients who received anti-EGFR 
therapy was small, we need for increasing the number of 
RCRC patients in future. However, we did demonstrate that 
RCRC was significantly associated with genetic alterations 
associated with resistance to anti-EGFR therapy, which 
provides a plausible mechanism of resistance to anti-EGFR 
therapy in patients with RCRC.
In conclusion, we show RCRC is more likely to 
harbor genetic alterations associated with resistance to 
anti-EGFR therapy compared with LCRC, and primary 
tumor sidedness is a surrogate for a non-random 
distribution of genetic alterations in CRC.
MATERIALS AND METHODS
Patients
This retrospective analysis was performed in 
accordance with the Helsinki Declaration and the 
protocol was approved by the Ethics Committee of the 
School of Medicine, Niigata University. We randomly 
selected and enrolled 201 patients diagnosed with stage 
I - IV CRC based on the 7th edition of the American 
Joint Committee on Cancer staging manual [28] who 
had a primary tumor resection between 2009 and 2015 
at Niigata University Medical and Dental Hospital or 
Niigata Cancer Center Hospital. In this analysis, we 
included the 201 independent individuals, all unrelated, 
confirmed from our database and medical charts. Patients 
with familial adenomatous polyposis or inflammatory 
bowel disease were excluded.
Primary tumor sidedness and clinicopathological 
characteristics
Primary tumor location was determined by operative 
findings. Cancer in the cecum, ascending colon, hepatic 
flexure, or transverse colon was classified as right-sided; 
and cancer in the splenic flexure, descending colon, 
sigmoid colon, rectosigmoid, or rectum was classified as 
left-sided [29, 30]. Histopathological features associated 
with RCRC, such as medullary type, mucinous type, 
signet ring type, and tumor-infiltrating lymphocytes 
Primary tumor sidedness
P-valueVariable Right (n = 8) Left (n = 41)
Alterations in TK receptors/RAS pathway/PI3K 
pathway excluding KRAS and BRAF mutations
 Absence 7 20 0.059
 Presence 1 21
Alterations in TK receptors/RAS pathway/PI3K 
pathway
 0 3 15 0.492
 1 5 20
 2 0 6
 All wild-type 3 15 0.999
 Mutant-type 5 26
Anti-EGFR drug
 Cetuximab 2 9 0.999
 Panitumumab 6 32
Anti-EGFR therapy
 Initial therapy 3 9 0.386
 Subsequent therapy 5 32
Chemotherapy added to anti-EGFR therapy
 Oxaliplatin-based 3 7 0.195
 Irinotecan-based 3 29
 Anti-EGFR drug only 2 5
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were analyzed by a previously reported method [31]. 
MutL homologue 1 (MLH1)/MutS homologue 2 
(MSH2) status was evaluated in 110 of the 201 patients 
by immunohistochemistry with anti-MLH1 (1:50; BD 
Biosciences PharMingen, San Diego, CA) and anti-MSH2 
(1:50; Leica Microbiosystems, Tokyo, Japan) antibodies. 
Hypermutation was defined as a tumor with MSI-H and/
or high tumor mutation burden (TMB), as described 
previously [25], using CGS. TMB was calculated as the 
number of non-synonymous mutations per megabase 
of sequence in the panel (panel size = 1.3 Mb). To be 
classified as hypermutated, the threshold of TMB was 
set as the lowest TMB observed in tumors with MSI-H. 
Tumors with mutations in POLE or other DNA repair 
genes can have very high TMB but not show MSI-H [25].
CGS analysis of primary tumors
Archival tissue in the form of formalin-fixed, 
paraffin-embedded (FFPE) tumor or unstained tissue 
sections obtained during primary tumor resection were 
used for CGS. An independent pathologist evaluated 
tumor content in each sample using hematoxylin and 
eosin-stained slides to ensure > 50% tumor content was 
present. Where applicable, unstained slides were macro-
dissected to enrich for tumor content and DNA was 
extracted using a BioStic FFPE Tissue DNA Isolation Kit 
(Mo Bio Laboratories, Inc., Carlsbad, CA). All sample 
preparation, CGS, and analytics were performed in a 
CLIA/CAP-accredited laboratory (KEW Inc., Cambridge, 
MA). DNA fragment (50–150 ng) libraries were prepared 
and enriched for the CancerPlex 415-gene panel (KEW 
Inc.) [25, 26], a large clinically validated panel of 415 
genes enriched for coding regions and selected introns of 
known cancer-related genes. Sequencing was performed 
on Illumina MiSeq and NextSeq platforms with an 
average 500× sequencing depth. Genomic data were 
then processed through a proprietary bioinformatics 
platform and knowledgebase to identify multiple classes 
of genomic abnormalities including single nucleotide 
substitutions, small insertions/deletions, copy number 
variations, and translocations. Single nucleotide variant 
(SNV) and insertion or deletion (indel) calling were only 
performed in genomic regions intended to be captured by 
the assay (region of interest). We set a standard threshold 
of 10% allelic fraction for calling SNVs and indels to 
focus on primary truncal driver mutations and avoid 
subclonal events. Copy number variants were called for 
exons as well as globally. We segmented regions using a 
Fused-Lasso method and export the results to a VCF file. 
The threshold for gain was > 2.5 fold and for loss was 
< 0.5 fold. Variants were filtered or flagged according to 
technical quality (e.g. coverage, allelic fraction, number 
of supporting reads), presence in previously characterized 
normal samples, or presence/absence in the following 
databases: dbSNP, ExAC, COSMIC, ClinVar, and KEW. 
SNVs and indels in VCF format were annotated using 
SnpEff and the output was adapted according to HGVS 
recommendations [25, 26].
Genetic alterations in TK receptors and the RAS 
and PI3K pathways in RCRC and LCRC
Genetic alterations of TK receptors (ERBB2, MET, 
EGFR, FGFR1, and PDGFRA), RAS pathway (KRAS, 
NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway 
(PTEN and PIK3CA) were analyzed using CGS of the 415-
gene panel. We defined patients who had no alterations in 
all 12 genes as “all wild-type”; theoretically, these patients 
should respond to anti-EGFR therapy [22, 23]. We defined 
the remaining patients with genetic alterations as “mutant-
type”. We also estimated the incidence of “all wild-type” 
for RCRC and LCRC. In this analysis of 201 patients, 
49 received anti-EGFR therapy. In these 49 patients, we 
investigated the efficacy of anti-EGFR therapy according 
to primary tumor sidedness and genetic alterations 
associated with resistance to anti-EGFR therapy.
Statistical analysis
Statistical analyses were performed with IBM 
SPSS Statistics 22 (IBM Japan, Inc., Tokyo, Japan). 
A Fisher’s exact test or Chi-squared test was used to 
evaluate associations between primary tumor sidedness 
and clinicopathological characteristics, and primary tumor 
sidedness and genetic alterations were evaluated with 
CGS. The association between primary tumor sidedness 
and genetic alterations associated with resistance to anti-
EGFR therapy was examined by Fisher’s exact test or 
Chi-squared test. PFS rates in patients treated with anti-
EGFR therapy (cetuximab or panitumumab) in addition 
to cytotoxic chemotherapy were estimated using Kaplan-
Meier analysis. A log-rank test was used to assess for a 
significant difference between right-sided and left-sided 
tumors. P-values < 0.05 were considered statistically 
significant.
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